好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Is Relapse Pattern Predictable in Relapsing-Remitting Multiple Sclerosis?
MS and Related Diseases
P04 - (-)
142
BACKGROUND: The clinical course of MS is variable. Studies have shown early characteristics that might predict disease course and a few studies have examined initial relapse characteristics to discern if it helps predict subsequent relapses. We undertook a comprehensive analysis of multiple relapse characteristics including relapse location, symptoms, ethnicity, age at onset and relapse recovery to determine if relapses have an inherent pattern in individuals.
DESIGN/METHODS: Chart review of 750 patients in our database. Statistical analysis: non-parametric correlations.
RESULTS: Preliminary analysis of 42 patients with 2 or more relapses showed that there was a highly significant correlation between initial relapse symptoms, location and recovery to subsequent relapses (<0.01). There appeared to be a correlation between gender and relapse symptoms (<0.05). There did not appear to be a correlation between age/ethnicity and relapse pattern. We plan analysis of 750 patients and provide details of any specific associations.
CONCLUSIONS: The course of MS provides clues to the underlying disease process and insights into the pathophysiology. Study showed that areas of injury and remyelination are most vulnerable to subsequent demyelination. Also the extent of remyelination seems to be variable among individuals with MS. Clinical features that corroborate with such pathological findings furthers understanding of this disease. If one can demonstrate that specific disease patterns are set early in the disease course in a given individual with MS, this would help choosing the most appropriate and optimal treatment for a patient early in the course of the disease.
Authors/Disclosures
Danielle Kirchhof
PRESENTER 		No disclosure on file
Susan Gauthier, DO (Weill Cornell Medicine) Dr. Gauthier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Gauthier has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Gauthier has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Gauthier has received research support from Genentech.
Nancy M. Nealon, MD (Cornell Medical Center) Dr. Nealon has nothing to disclose.
Bill Nikolov No disclosure on file
Timothy K. Vartanian, MD, PhD (Weill Cornell Medical College) Dr. Vartanian has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Vartanian has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Vartanian has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Vartanian has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tisch MS Center. Dr. Vartanian has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen.
Jai Perumal, MD Dr. Perumal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Perumal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for T G therapeutics. Dr. Perumal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono.
Aneesh B. Singhal, MD, FAAN (Massachusetts General Hospital) An immediate family member of Dr. Singhal has received personal compensation for serving as an employee of Biogen. Dr. Singhal has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Medicolegal Firms. Dr. Singhal has received research support from NIH-NINDS. Dr. Singhal has received publishing royalties from a publication relating to health care. Dr. Singhal has received publishing royalties from a publication relating to health care. Dr. Singhal has received personal compensation in the range of $500-$4,999 for serving as a Honorarium (好色先生) with Biogen.